Selected research
Industry Research
Chain Pharmacy Prescription Drugs Industry Research Report 2026
Market perspective
The global Chain Pharmacy Prescription Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Chain Pharmacy Prescription Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Chain Pharmacy Prescription Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Chain Pharmacy Prescription Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Chain Pharmacy Prescription Drugs include Yifeng Pharmacy Chain, Yixintang Pharmaceutical Group, Laobaixing Pharmacy Chain, Sinopharm Group, DaShenLin Pharmaceutical Group, Walgreens Boots Alliance, Walgreens, Superdrug and Rite Aid, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Chain Pharmacy Prescription Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Chain Pharmacy Prescription Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Chain Pharmacy Prescription Drugs Market by Company
Yifeng Pharmacy Chain
Yixintang Pharmaceutical Group
Laobaixing Pharmacy Chain
Sinopharm Group
DaShenLin Pharmaceutical Group
Walgreens Boots Alliance
Walgreens
Superdrug
Rite Aid
Pharmacy2U
Health Mart
CVS Health
Celesio
Boots UK
Alphega Pharmacy
Chain Pharmacy Prescription Drugs Segment by Type
Tumor Treatment Drugs
Cardiovascular Drugs
Digestive System Drugs
Nervous System Drugs
Endocrine System Drugs
Immune Modulators
Anti-Infective Drugs
Respiratory Drugs
Others
Chain Pharmacy Prescription Drugs Segment by Application
Prophylaxis
Chronic Disease Management
Clinical Treatment
Scientific Research
Others
Chain Pharmacy Prescription Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chain Pharmacy Prescription Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chain Pharmacy Prescription Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chain Pharmacy Prescription Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Chain Pharmacy Prescription Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tumor Treatment Drugs
- Cardiovascular Drugs
- Digestive System Drugs
- Nervous System Drugs
- Endocrine System Drugs
- Immune Modulators
- Anti-Infective Drugs
- Respiratory Drugs
- Others
Applications
- Prophylaxis
- Chronic Disease Management
- Clinical Treatment
- Scientific Research
- Others
Companies covered
- Yifeng Pharmacy Chain
- Yixintang Pharmaceutical Group
- Laobaixing Pharmacy Chain
- Sinopharm Group
- DaShenLin Pharmaceutical Group
- Walgreens Boots Alliance
- Walgreens
- Superdrug
- Rite Aid
- Pharmacy2U
- Health Mart
- CVS Health
- Celesio
- Boots UK
- Alphega Pharmacy
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Chain Pharmacy Prescription Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tumor Treatment Drugs
- 2.2.3 Cardiovascular Drugs
- 2.2.4 Digestive System Drugs
- 2.2.5 Nervous System Drugs
- 2.2.6 Endocrine System Drugs
- 2.2.7 Immune Modulators
- 2.2.8 Anti-Infective Drugs
- 2.2.9 Respiratory Drugs
- 2.2.10 Others
- 2.3 Chain Pharmacy Prescription Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Prophylaxis
- 2.3.3 Chronic Disease Management
- 2.3.4 Clinical Treatment
- 2.3.5 Scientific Research
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Chain Pharmacy Prescription Drugs Breakdown Data by Type
- 3.1 Global Chain Pharmacy Prescription Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Chain Pharmacy Prescription Drugs Forecasted Market Size by Type (2027-2032)
4 Chain Pharmacy Prescription Drugs Breakdown Data by Application
- 4.1 Global Chain Pharmacy Prescription Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Chain Pharmacy Prescription Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Chain Pharmacy Prescription Drugs Market Perspective (2021-2032)
- 5.2 Global Chain Pharmacy Prescription Drugs Growth Trends by Region
- 5.2.1 Global Chain Pharmacy Prescription Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Chain Pharmacy Prescription Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Chain Pharmacy Prescription Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Chain Pharmacy Prescription Drugs Market Dynamics
- 5.3.1 Chain Pharmacy Prescription Drugs Industry Trends
- 5.3.2 Chain Pharmacy Prescription Drugs Market Drivers
- 5.3.3 Chain Pharmacy Prescription Drugs Market Challenges
- 5.3.4 Chain Pharmacy Prescription Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Chain Pharmacy Prescription Drugs Players by Revenue
- 6.1.1 Global Top Chain Pharmacy Prescription Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Chain Pharmacy Prescription Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Chain Pharmacy Prescription Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Chain Pharmacy Prescription Drugs Head Office and Area Served
- 6.4 Global Chain Pharmacy Prescription Drugs Players, Product Type & Application
- 6.5 Global Chain Pharmacy Prescription Drugs Manufacturers Established Date
- 6.6 Global Chain Pharmacy Prescription Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Chain Pharmacy Prescription Drugs Market Size (2021-2032)
- 7.2 North America Chain Pharmacy Prescription Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Chain Pharmacy Prescription Drugs Market Size by Country (2021-2026)
- 7.4 North America Chain Pharmacy Prescription Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Chain Pharmacy Prescription Drugs Market Size (2021-2032)
- 8.2 Europe Chain Pharmacy Prescription Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Chain Pharmacy Prescription Drugs Market Size by Country (2021-2026)
- 8.4 Europe Chain Pharmacy Prescription Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Chain Pharmacy Prescription Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Chain Pharmacy Prescription Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Chain Pharmacy Prescription Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Chain Pharmacy Prescription Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Chain Pharmacy Prescription Drugs Market Size (2021-2032)
- 10.2 South America Chain Pharmacy Prescription Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Chain Pharmacy Prescription Drugs Market Size by Country (2021-2026)
- 10.4 South America Chain Pharmacy Prescription Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Chain Pharmacy Prescription Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Chain Pharmacy Prescription Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Chain Pharmacy Prescription Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Chain Pharmacy Prescription Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Yifeng Pharmacy Chain
- 12.1.1 Yifeng Pharmacy Chain Company Information
- 12.1.2 Yifeng Pharmacy Chain Business Overview
- 12.1.3 Yifeng Pharmacy Chain Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.1.4 Yifeng Pharmacy Chain Chain Pharmacy Prescription Drugs Product Portfolio
- 12.1.5 Yifeng Pharmacy Chain Recent Developments
- 12.2 Yixintang Pharmaceutical Group
- 12.2.1 Yixintang Pharmaceutical Group Company Information
- 12.2.2 Yixintang Pharmaceutical Group Business Overview
- 12.2.3 Yixintang Pharmaceutical Group Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.2.4 Yixintang Pharmaceutical Group Chain Pharmacy Prescription Drugs Product Portfolio
- 12.2.5 Yixintang Pharmaceutical Group Recent Developments
- 12.3 Laobaixing Pharmacy Chain
- 12.3.1 Laobaixing Pharmacy Chain Company Information
- 12.3.2 Laobaixing Pharmacy Chain Business Overview
- 12.3.3 Laobaixing Pharmacy Chain Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.3.4 Laobaixing Pharmacy Chain Chain Pharmacy Prescription Drugs Product Portfolio
- 12.3.5 Laobaixing Pharmacy Chain Recent Developments
- 12.4 Sinopharm Group
- 12.4.1 Sinopharm Group Company Information
- 12.4.2 Sinopharm Group Business Overview
- 12.4.3 Sinopharm Group Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.4.4 Sinopharm Group Chain Pharmacy Prescription Drugs Product Portfolio
- 12.4.5 Sinopharm Group Recent Developments
- 12.5 DaShenLin Pharmaceutical Group
- 12.5.1 DaShenLin Pharmaceutical Group Company Information
- 12.5.2 DaShenLin Pharmaceutical Group Business Overview
- 12.5.3 DaShenLin Pharmaceutical Group Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.5.4 DaShenLin Pharmaceutical Group Chain Pharmacy Prescription Drugs Product Portfolio
- 12.5.5 DaShenLin Pharmaceutical Group Recent Developments
- 12.6 Walgreens Boots Alliance
- 12.6.1 Walgreens Boots Alliance Company Information
- 12.6.2 Walgreens Boots Alliance Business Overview
- 12.6.3 Walgreens Boots Alliance Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.6.4 Walgreens Boots Alliance Chain Pharmacy Prescription Drugs Product Portfolio
- 12.6.5 Walgreens Boots Alliance Recent Developments
- 12.7 Walgreens
- 12.7.1 Walgreens Company Information
- 12.7.2 Walgreens Business Overview
- 12.7.3 Walgreens Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.7.4 Walgreens Chain Pharmacy Prescription Drugs Product Portfolio
- 12.7.5 Walgreens Recent Developments
- 12.8 Superdrug
- 12.8.1 Superdrug Company Information
- 12.8.2 Superdrug Business Overview
- 12.8.3 Superdrug Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.8.4 Superdrug Chain Pharmacy Prescription Drugs Product Portfolio
- 12.8.5 Superdrug Recent Developments
- 12.9 Rite Aid
- 12.9.1 Rite Aid Company Information
- 12.9.2 Rite Aid Business Overview
- 12.9.3 Rite Aid Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.9.4 Rite Aid Chain Pharmacy Prescription Drugs Product Portfolio
- 12.9.5 Rite Aid Recent Developments
- 12.10 Pharmacy2U
- 12.10.1 Pharmacy2U Company Information
- 12.10.2 Pharmacy2U Business Overview
- 12.10.3 Pharmacy2U Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.10.4 Pharmacy2U Chain Pharmacy Prescription Drugs Product Portfolio
- 12.10.5 Pharmacy2U Recent Developments
- 12.11 Health Mart
- 12.11.1 Health Mart Company Information
- 12.11.2 Health Mart Business Overview
- 12.11.3 Health Mart Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.11.4 Health Mart Chain Pharmacy Prescription Drugs Product Portfolio
- 12.11.5 Health Mart Recent Developments
- 12.12 CVS Health
- 12.12.1 CVS Health Company Information
- 12.12.2 CVS Health Business Overview
- 12.12.3 CVS Health Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.12.4 CVS Health Chain Pharmacy Prescription Drugs Product Portfolio
- 12.12.5 CVS Health Recent Developments
- 12.13 Celesio
- 12.13.1 Celesio Company Information
- 12.13.2 Celesio Business Overview
- 12.13.3 Celesio Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.13.4 Celesio Chain Pharmacy Prescription Drugs Product Portfolio
- 12.13.5 Celesio Recent Developments
- 12.14 Boots UK
- 12.14.1 Boots UK Company Information
- 12.14.2 Boots UK Business Overview
- 12.14.3 Boots UK Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.14.4 Boots UK Chain Pharmacy Prescription Drugs Product Portfolio
- 12.14.5 Boots UK Recent Developments
- 12.15 Alphega Pharmacy
- 12.15.1 Alphega Pharmacy Company Information
- 12.15.2 Alphega Pharmacy Business Overview
- 12.15.3 Alphega Pharmacy Revenue in Chain Pharmacy Prescription Drugs Business (2021-2026)
- 12.15.4 Alphega Pharmacy Chain Pharmacy Prescription Drugs Product Portfolio
- 12.15.5 Alphega Pharmacy Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst